I guess it's safe to say the survival rate of this trial is 22% or higher, otherwise why would they bother.
The data to be presented are from a late-stage clinical trial and, if positive, would provide a basis for potential FDA approval of Provenge. The result could be presented the end of this month at the AUA's annual meeting in chicago if they are ready in time.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.